Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve.

Click here to learn how we are responding.

Responsive menu

Home

Designed to treat and control bleeds—
XYNTHA SOLOFUSE helps you live actively

Proven bleed control

When you need it. Demonstrated across clinical trials of previously treated patients (PTPs).

All-in-one reconstitution

Be prepared to bring it—All-in-one reconstitution in a travel-ready kit.

Not actual patients.

Free trial offer*

Patients prescribed XYNTHA for the first time may be eligible to receive a one-time,
1-month trial supply up to 20,000 IU at no cost.

*Terms and conditions apply.

Resources and support

More than just factor—Take a look at some of the resources and support Pfizer Hemophilia has to offer.

Environmentally friendly
travel-ready kit

The cardboard travel-ready kit still comes compact and loaded with everything you need to infuse on the go.

Important Safety Information for XYNTHA

Call your health care provider or go to the emergency department right away if you have any of the following symptoms because these may be signs of a serious allergic reaction: wheezing, difficulty breathing, chest tightness, turning blue (look at lips and gums), fast heartbeat, swelling of the face, faintness, rash, low blood pressure, or hives. XYNTHA contains trace amounts of hamster protein. You may develop an allergic reaction to these proteins. Tell your health care provider if you have had an allergic reaction to hamster protein.
Call your health care provider right away if bleeding is not controlled after using XYNTHA; this may be a sign of an inhibitor, an antibody that may stop XYNTHA from working properly. Your health care provider may need to take blood tests to monitor for inhibitors.
Across all clinical studies, the most common side effects (10% or more) with XYNTHA in adult and pediatric previously treated patients were headache (24% of subjects), joint pain (23%), fever (23%), and cough (12%). Other side effects reported in 5% or more of patients were diarrhea, vomiting, and weakness.
XYNTHA is an injectable medicine administered by intravenous (IV) infusion. You may experience local irritation when infusing XYNTHA after reconstitution in XYNTHA^® SOLOFUSE^®.

What is XYNTHA?

XYNTHA^® Antihemophilic Factor (Recombinant) is indicated in adults and children for on-demand treatment and control of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for the prevention of bleeding during surgery in patients with hemophilia A.

XYNTHA does not contain von Willebrand factor and, therefore, is not indicated for von Willebrand disease.

Please see full Prescribing Information for XYNTHA and XYNTHA SOLOFUSE.

Patients should always ask their doctors for medical advice about adverse events.
You are encouraged to report adverse events related to Pfizer products by calling 1.800.438.1985 (U.S. only). If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1.800.FDA.1088.

© 2020 Pfizer Inc. All rights reserved.

The health information in this site is provided for educational purposes only and is not intended to replace discussions with a health care provider. All decisions regarding patient care must be made with a health care provider, considering the unique characteristics of the patient. The product information provided in this site is intended only for residents of the United States. The products discussed in this site may have different product labeling in different countries.

February 2020

AdChoices

PP-XYN-USA-0403